Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus

This publication has 71 references indexed in Scilit:

• The heart of the matter: Right heart imaging indicators for treatment escalation in pulmonary arterial hypertension
  Pulmonary Circulation, 2023
• REVEAL LITE 2 RISK ASSESSMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION FROM THE GRIPHON STUDY: A POST-HOC ANALYSIS DEMONSTRATES ASSOCIATION OF RISK STATUS WITH LONG-TERM OUTCOMES
  Chest, 2021
• Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension
  Chest, 2021
• Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
  Chest, 2021
• Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents
  Chest, 2020
• Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension
  Chest, 2020
• Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
  American Journal of Cardiovascular Drugs, 2018
• Safety and Long-Term Efficacy of Transition from Sildenafil to Tadalafil due to Side Effects in Patients with Pulmonary Arterial Hypertension
  Lung, 2014
• Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations
  Lung, 2012
• Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
  European Journal of Clinical Pharmacology, 2007